5.13  -0.605 (-10.55%)		07-15 16:00
Open: 5.35 High: 5.59 Volume: 236,946		Pre. Close: 5.735 Low: 4.9001 Market Cap: 8(M)

Short term
Mid term
Targets	6-month :	8.22	1-year :	11.53
Resists	First :	7.04	Second :	9.88
Pivot price	3.78
Supports	First :	2.46	Second :	2.04
MAs	MA(5) :	5.99	MA(20) :	3.52
	MA(100) :	3.26	MA(250) :	4.25
MACD	MACD :	0.6	Signal :	0.3
%K %D	K(14,3) :	42.4	D(3) :	47.3
RSI	RSI(14): 62.2
52-week	High :	12.31	Low :	1.94

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ EVOK ] has closed below upper band by 29.3%. Bollinger Bands are 356.1% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	5.83 - 5.87	5.87 - 5.89
Low:	5.23 - 5.27	5.27 - 5.3
Close:	5.67 - 5.74	5.74 - 5.79

Evoke Pharma, Inc., a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females. The company markets its products to gastroenterologists, internal medicine specialists, primary care physicians, and select health care providers. Evoke Pharma, Inc. was incorporated in 2007 and is headquartered in Solana Beach, California.

Thu, 10 Jul 2025
Evoke Pharma skyrockets on patent allowance for diabetes nasal spray drug - Mugglehead Magazine

Wed, 09 Jul 2025
Evoke Pharma (EVOK) Soars 162.78% on Patent Extension - AInvest

Wed, 09 Jul 2025
Evoke Pharma (EVOK) Shares Skyrocket On New Patent: What's Going On? - Benzinga

Wed, 09 Jul 2025
Evoke Pharma: Is the Bounce Back Real? - StocksToTrade

Wed, 09 Jul 2025
EVOK Stock: Boom or Bust? - timothysykes.com

Wed, 09 Jul 2025
Evoke Pharma stock soars after receiving patent allowance for GIMOTI - Investing.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	1 (M)
Shares Float	1 (M)
Held by Insiders	1.3 (%)
Held by Institutions	16.2 (%)
Shares Short	18 (K)
Shares Short P.Month	27 (K)

EPS	-1.24
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	2.89
Profit Margin	-43.8 %
Operating Margin	-42.3 %
Return on Assets (ttm)	-21.8 %
Return on Equity (ttm)	-108.8 %
Qtrly Rev. Growth	77.5 %
Gross Profit (p.s.)	7.57
Sales Per Share	7.77
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	-4 (M)
Levered Free Cash Flow	-2 (M)

PE Ratio	-4.16
PEG Ratio	0
Price to Book value	1.76
Price to Sales	0.65
Price to Cash Flow	-1.97

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.